• By: Yuka Osada
• On: June 18, 2026

From Foreign Phase 1 Studies to U.S. Phase 2: Getting EOP1 Meetings Right

• By: Yuka Osada
• On: June 11, 2026

How Regulators Review Drug Brand Names: US, EU, & Japan

• By: Yuka Osada
• On: May 21, 2026

FDA Platform Technology: What Sponsors Need to Know Now

• By: Yuka Osada
• On: May 14, 2026

Cracking U.S. FDA Labeling and Claims for MedTech Startups

• By: Yuka Osada
• On: May 7, 2026

Latest News: Proposed US-FDA Scrutiny on Cross-Border Clinical Data!

• By: Yuka Osada
• On: April 16, 2026

2026 User Fees Update! US FDA, EMA, and PMDA

• By: Yuka Osada
• On: April 2, 2026

Why US FDA Demands Human Factors Engineering for Devices?

• By: Yuka Osada
• On: March 12, 2026

Ready for US-FDA E2B(R3) Safety Reporting from April 1st?

• By: Yuka Osada
• On: March 5, 2026

Evidence Is the Product – Rethinking U.S FDA Device Testing

• By: Yuka Osada
• On: February 26, 2026

Are U.S. FDA Regulatory Consultants Required in this AI-Era?